MARKET

XNCR

XNCR

Xencor
NASDAQ

Real-time Quotes | Nasdaq Last Sale

37.75
+0.64
+1.72%
After Hours: 37.75 0 0.00% 16:12 09/25 EDT
OPEN
37.02
PREV CLOSE
37.11
HIGH
37.97
LOW
36.96
VOLUME
194.88K
TURNOVER
--
52 WEEK HIGH
43.90
52 WEEK LOW
19.35
MARKET CAP
2.16B
P/E (TTM)
-26.7730
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Week Ahead In Biotech: FDA Decisions For Mesoblast And Eton, Coronavirus Vaccine Updates
Biotech stock reversed course last week, dragged lower by the broader market weakness.
Benzinga · 16h ago
Did You Miss Xencor's (NASDAQ:XNCR) Impressive 218% Share Price Gain?
When you buy a stock there is always a possibility that it could drop 100%. But on a lighter note, a good company can...
Simply Wall St. · 3d ago
How To Avoid The Noise And Invest For Long-Term Success
Let's face it, today's retail investor is bombarded with information, and parsing through what is useful and what is not can be challenging.Avoiding noise and executing under pressure are critical to investing success.I've been managing custom-built equity portfolios since 2012, and hope to engage with those on Seeking Alpha interested in long-term investment success.I will look to do this with the tools I've developed to manage portfolios.
Seekingalpha · 5d ago
The Daily Biotech Pulse: Roche's COVID Combo Therapy Reduces Need For Ventilation, ESMO Presentations
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 17)
Benzinga · 09/18 11:30
Xencor to Present at the 2020 Cantor Fitzgerald Virtual Global Healthcare Conference
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will present at the Cantor Fitzgerald Virtual Global Healthcare Conference on Tuesday, September
Business Wire · 09/09 21:01
Xencor to Present Initial Data from the Phase 1 Study of Tidutamab in Neuroendocrine Tumors at NANETS’ Multidisciplinary NET Medical Virtual Symposium
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that initial data from its ongoing Phase 1 dose-escalation study of tidutamab (XmAb®18087), an SSTR2 x CD3 bispecific
Business Wire · 09/09 12:01
Xencor teams up with MD Anderson on XmAb cancer treatments
Xencor (XNCR) will collaborate with The University of Texas MD Anderson Cancer Center to investigate treatments for a range of cancers leveraging the company's line-up of XmAb drug candidates, including
Seekingalpha · 09/03 12:35
Xencor to Present at Upcoming Investor Conferences
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will participate in three upcoming conferences:
Business Wire · 08/05 20:01
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of XNCR. Analyze the recent business situations of Xencor through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 12 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average XNCR stock price target is 45.36 with a high estimate of 56.00 and a low estimate of 28.00.
EPS
Institutional Holdings
Institutions: 210
Institutional Holdings: 63.10M
% Owned: 110.24%
Shares Outstanding: 57.24M
TypeInstitutionsShares
Increased
80
6.66M
New
41
219.17K
Decreased
27
598.89K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.04%
Pharmaceuticals & Medical Research
+1.58%
Key Executives
President/Chief Executive Officer/Founder/Director
Bassil Dahiyat
Chief Financial Officer/Vice President
John Kuch
Senior Vice President/Chief Scientific Officer
John Desjarlais
Senior Vice President
Allen Yang
Vice President/General Counsel/Secretary
Celia Eckert
Lead Director/Independent Director
A. Montgomery
Vice President
Jeremy Grunstein
Vice President
Eric Kowack
Vice President
Kirk Rosemark
Other
Julie Casciani
Lead Director/Independent Director
A. Bruce Montgomery
Independent Director
Ellen Feigal
Independent Director
Kevin Gorman
Independent Director
Kurt Gustafson
Independent Director
Yujiro Hata
Independent Director
Richard Ranieri
Independent Director
Dagmar Rosa-Bjorkeson
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About XNCR
Xencor, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases. It is also developing a pipeline of bispecific antibody candidates using its heterodimer Fc bispecific technology: XmAb14045, which is in a Phase I trial for the treatment of acute myeloid leukemia (AML); XmAb13676, which is in a Phase I trial for the treatment of B-cell malignancies; XmAb18087, which is in preclinical development for the treatment of neuroendocrine tumors, and XmAb20717, which is in preclinical development for the treatment of various cancers and is its dual checkpoint inhibitor.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Xencor Inc stock information, including NASDAQ:XNCR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XNCR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading XNCR stock methods without spending real money on the virtual paper trading platform.